Text Size

Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by IRCCS Policlinico S. Matteo.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier:
NCT00910130
First received: May 28, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted
  Purpose

The purpose of this study is to determine whether Retinol binding protein 4 has a role in insulin resistance development in patients suffering from end stage renal disease on hemodialysis.


Condition
Insulin Resistance
Diabetes
End Stage Renal Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by IRCCS Policlinico S. Matteo:

Biospecimen Retention:   Samples With DNA

Serum Subcutaneous adipose tissue


Estimated Enrollment: 30
Study Start Date: July 2008
Groups/Cohorts
End Stage Renal Disease
Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
Control
Healthy people, with normal Renal Function and without Diabetes, matched with "ESRD group" for age, gender, BMI

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Ambulatory patients or primary care clinic for "End Stage Renal Disease group;" Blood donors or primary care clinic for "Control group"

Criteria

Inclusion Criteria:

  • Hemodialysis for "End Stage Renal Disease group"
  • Normal Renal Function for "Control group"

Exclusion Criteria:

  • Diabetes
  • Malnutrition
  • Malignancy
  • Acute Infection
  • Chronic Active Infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00910130

Contacts
Contact: Giovanni Piotti, MD +390382502590 gpiotti@yahoo.it
Contact: Teresa Rampino, MD +390382503896 t.rampino@smatteo.pv.it

Locations
Italy
Giovanni Piotti Recruiting
Pavia, Italy, 27100
Contact: Giovanni Piotti, MD     +390382502590     gpiotti@yahoo.it    
Contact: Teresa Rampino, MD     +390382503896     t.rampino@smatteo.pv.it    
Principal Investigator: Giovanni Piotti, MD            
Sub-Investigator: Elisa Gabanti            
Sub-Investigator: Esposito Pasquale, MD            
Sub-Investigator: Marilena Gregorini, MD, PHD            
Sub-Investigator: Giulia Bedino, MD            
Principal Investigator: Francesca Bosio, MD            
Sponsors and Collaborators
IRCCS Policlinico S. Matteo
Investigators
Principal Investigator: Giovanni Piotti, MD Unit Of Nephrology, Dialysis And Transpantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy
Study Director: Teresa Rampino, MD Unit Of Nephrology, Dialysis And Transpantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy
Study Chair: Antonio Dal Canton, MD Unit Of Nephrology, Dialysis And Transpantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy
  More Information

Publications:

Responsible Party: Giovanni Piotti, MD, Unit Of Nephrology, Dialysis And Transplantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy
ClinicalTrials.gov Identifier: NCT00910130     History of Changes
Other Study ID Numbers: RBP4
Study First Received: May 28, 2009
Last Updated: May 28, 2009
Health Authority: Italy: National Bioethics Committee

Keywords provided by IRCCS Policlinico S. Matteo:
Retinol Binding Protein 4
Insulin Resistance
Diabetes
 End Stage Renal Disease
Dialysis
Nutrition

Additional relevant MeSH terms:
Diabetes Mellitus
Insulin Resistance
Kidney Diseases
Kidney Failure, Chronic
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperinsulinism
Urologic Diseases
Renal Insufficiency, Chronic
 Renal Insufficiency
Insulin
Vitamin A
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on June 17, 2013